SCHEMBL1085293

SCHEMBL1085293

Cc1cc(-c2cccc(OC(F)(F)F)c2)nc(C)c1C(=O)N1CCC(N2CCCC2CO)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
MAP3K7 O43318 1/20 0.38
TAB1 Q15750 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CCR5 P51681 1/20 0.38
SLC6A7 Q99884 1/20 0.38
DGAT2 Q96PD7 1/20 0.37
HSD11B1 P28845 1/20 0.37
MGLL Q99685 2/20 0.37
USP30 Q70CQ3 2/20 0.36
EPHX2 P34913 1/20 0.36
TRPV1 Q8NER1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083695 1.00 ALDH1A1 (0.38) ALDH1A1HPGDMAP3K7TAB1HCRTR1
SCHEMBL1085435 0.89 CHRNB2 (0.42) ALDH1A1HPGDHCRTR1HCRTR2KDM4E
SCHEMBL1085607 0.89 TRPV1 (0.46) ALDH1A1TRPV1MEN1KMT2ASPHK2
SCHEMBL1083712 0.89 TRPV1 (0.46) ALDH1A1TRPV1MEN1KMT2ASPHK2
SCHEMBL1083708 0.88 CCR5 (0.42) MAP3K7TAB1HCRTR1HCRTR2CCR5
SCHEMBL1085077 0.88 CCR5 (0.42) MAP3K7TAB1HCRTR1HCRTR2CCR5
SCHEMBL1083727 0.86 L3MBTL3 (0.43) SLC6A7DGAT2HSD11B1MGLL
SCHEMBL1083744 0.85 MAPK7 (0.41) MAP3K7TAB1HCRTR1HCRTR2SLC6A7
SCHEMBL1085088 0.85 MAPK7 (0.41) MAP3K7TAB1HCRTR1HCRTR2SLC6A7
SCHEMBL1719267 0.82 MAP3K7 (0.38) MAP3K7TAB1HCRTR1HCRTR2SLC6A7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 ALDH1A1 1202/4885HPGD 2707/4885MAP3K7 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.